標靶治療於急性骨髓性白血病成本效益分析

Chia-Hsun Lee; 李佳勳

請用此 Handle URI 來引用此文件： http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84675

完整後設資料紀錄

DC 欄位	值	語言
dc.contributor.advisor	陳秀熙(Hsiu-Hsi Chen),侯信安(Hsin-An Hou)
dc.contributor.author	Chia-Hsun Lee	en
dc.contributor.author	李佳勳	zh_TW
dc.date.accessioned	2023-03-19T22:20:06Z	-
dc.date.copyright	2022-10-17
dc.date.issued	2022
dc.date.submitted	2022-09-28
dc.identifier.citation	Hou, H. A., Lin, C. C., Chou, W. C., Liu, C. Y., Chen, C. Y., Tang, J. L., Lai, Y. J., Tseng, M. H., Huang, C. F., Chiang, Y. C., Lee, F. Y., Kuo, Y. Y., Lee, M. C., Liu, M. C., Liu, C. W., Lin, L. I., Yao, M., Huang, S. Y., Ko, B. S., . . . Tien, H. F. (2014). Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia, 28(1), 50-58. https://doi.org/10.1038/leu.2013.236 Hou, H.-A., & Tien, H.-F. (2020). Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. Journal of biomedical science, 27(1), 1-13. Tsai, C. H., Yao, C. Y., Tien, F. M., Tang, J. L., Kuo, Y. Y., Chiu, Y. C., Lin, C. C., Tseng, M. H., Peng, Y. L., Liu, M. C., Liu, C. W., Yao, M., Lin, L. I., Chou, W. C., Chen, C. Y., Hou, H. A., & Tien, H. F. (2019). Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. EBioMedicine, 40, 240-250. https://doi.org/10.1016/j.ebiom.2019.01.022 Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., Magro, D., De Fabritiis, P., Muus, P., Alimena, G., Mancini, M., Hagemeijer, A., Paolini, F., Vignetti, M., Fazi, P., . . . Baron, F. (2016). Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. Journal of Clinical Oncology, 34, 972. https://doi.org/10.1200/JCO.2015.64.0060 Arenaza, A., Diez, R., Esteve, J., Di Nicolantonio, R., Gostkorzewicz, J., Martínez, C., Llinàs, D. M., Martinez-Lopez, J., Montesinos, P., & Moure-Fernández, A. (2019). Cost-effectiveness of midostaurin in the treatment of acute myeloid leukemia with the FLT3 mutation in Spain. ClinicoEconomics and Outcomes Research: CEOR, 11, 683. Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., de Revel, T., Gastaud, L., de Gunzburg, N., Contentin, N., Henry, E., Marolleau, J.-P., Aljijakli, A., Rousselot, P., Fenaux, P., . . . Dombret, H. (2012). Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. The Lancet, 379(9825), 1508-1516. https://doi.org/https://doi.org/10.1016/S0140-6736(12)60485-1 Christoph Röllig, G. J. O. (2021). Acute myeloid leukemia. Springer Cham. https://doi.org/https://doi.org/10.1007/978-3-030-72676-8 DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., Koller, E., Havelange, V., Leber, B., Esteve, J., Wang, J., Pejsa, V., Hájek, R., Porkka, K., Illés, Á., . . . Pratz, K. W. (2020). Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine, 383(7), 617-629. https://doi.org/10.1056/NEJMoa2012971 Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., Levine, R. L., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G. J., Sanz, M., Sierra, J., Tallman, M. S., Tien, H.-F., . . . Bloomfield, C. D. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129(4), 424-447. https://doi.org/10.1182/blood-2016-08-733196 Falini, B., Brunetti, L., & Martelli, M. P. (2021). How I diagnose and treat NPM1-mutated AML. Blood, 137(5), 589-599. https://doi.org/10.1182/blood.2020008211 Forsythe, A., Brandt, P. S., Dolph, M., Patel, S., Rabe, A. P. J., & Tremblay, G. (2018). Systematic review of health state utility values for acute myeloid leukemia. Clinicoecon Outcomes Res, 10, 83-92. https://doi.org/10.2147/ceor.S153286 Huang, H.-H., Chen, C.-M., Wang, C.-Y., Hsu, W. W.-Y., Chen, H.-M., Ko, B.-S., & Hsiao, F.-Y. (2022). The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan. PLOS ONE, 17(1), e0261871. https://doi.org/10.1371/journal.pone.0261871 Jilu Tang, H. L. (2000/05/10). 一本讀通血癌. 天下生活股份有限公司. Juliusson, G., Hagberg, O., Lazarevic, V. L., Ölander, E., Antunovic, P., Cammenga, J., Wennström, L., Möllgård, L., Brune, M., Jädersten, M., Deneberg, S., Lehmann, S., Derolf, Å. R., Höglund, M., & Registry, f. t. S. A. (2019). Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood, 134(18), 1558-1561. https://doi.org/10.1182/blood.2019001728 Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021). Acute myeloid leukemia: current progress and future directions. Blood cancer journal, 11(2), 41-41. https://doi.org/10.1038/s41408-021-00425-3 Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., Kuo, C.-Y., Oriol, A., Ravandi, F., Faderl, S., Delaunay, J., Lysák, D., Minden, M., & Arthur, C. (2012). Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(21), 2670-2677. https://doi.org/10.1200/JCO.2011.38.9429 Kharfan-Dabaja, M. A., Hamadani, M., Reljic, T., Pyngolil, R., Komrokji, R. S., Lancet, J. E., Fernandez, H. F., Djulbegovic, B., & Kumar, A. (2013). Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol, 163(3), 315-325. https://doi.org/10.1111/bjh.12528 Komorowski M, R. J. (2016). Markov Models and Cost Effectiveness Analysis: Applications in Medical Research. 2016 Sep 10. In: Secondary Analysis of Electronic Health Records [Internet]. Cham (CH): Springer; 2016. Chapter 24. . https://doi.org/10.1007/978-3-319-43742-2_24 Li, Y.-C., Shih, Y.-H., Chen, T.-C., Gau, J.-P., Su, Y.-C., Chen, M.-H., Hsu, C.-Y., Liao, C.-S., & Teng, C.-L. (2021). Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia. Journal of Clinical Medicine, 10, 5768. https://doi.org/10.3390/jcm10245768 Marchetti, M., Albertin, L., Limberti, G., & Canicattì, M. (2022). Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy. Expert Opinion on Pharmacotherapy, 23(2), 263-272. https://doi.org/10.1080/14656566.2021.2014453 Middeke, J. M., Metzeler, K. H., Röllig, C., Krämer, M., Eckardt, J.-N., Stasik, S., Greif, P. A., Spiekermann, K., Rothenberg-Thurley, M., Krug, U., Braess, J., Krämer, A., Hochhaus, A., Brümmendorf, T. H., Naumann, R., Steffen, B., Einsele, H., Schaich, M., Burchert, A., . . . Thiede, C. (2022). Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Advances, 6(5), 1394-1405. https://doi.org/10.1182/bloodadvances.2021004934 Miyamoto, T., Sanford, D., Tomuleasa, C., Hsiao, H.-H., Olivera, L. J. E., Enjeti, A. K., Gimenez Conca, A., Castillo, T. B. d., Girshova, L., Martelli, M. P., Guvenc, B., Delgado, A., Duan, Y., Garbayo Guijarro, B., Llamas, C., & Lee, J.-H. (2022). Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy*. Leukemia & Lymphoma, 63(4), 928-938. https://doi.org/10.1080/10428194.2021.2002321 Numan, Y., Abdel Rahman, Z., Grenet, J., Boisclair, S., Bewersdorf, J. P., Barth, D., Zeidan, A. M., Yilmaz, M., Dinner, S., Deutsch, Y. E., Frankfurt, O., Litzow, M., Al-Kali, A., Foran, J. M., Sproat, L. Z., Jovanovic, B., Daver, N., Perl, A. E., & Altman, J. K. (2020). Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors. Blood, 136, 5-7. https://doi.org/https://doi.org/10.1182/blood-2020-137251 Perl, A. E. (2017). The role of targeted therapy in the management of patients with AML. Hematology. American Society of Hematology. Education Program, 2017(1), 54-65. https://doi.org/10.1182/asheducation-2017.1.54 Reljic, T., Sehovic, M., Lancet, J., Kim, J., Al Ali, N., Djulbegovic, B., & Extermann, M. (2020). Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis. Journal of Geriatric Oncology, 11(8), 1293-1308. https://doi.org/https://doi.org/10.1016/j.jgo.2020.06.019 Richard-Carpentier, G., & DiNardo, C. D. (2019). Single-agent and combination biologics in acute myeloid leukemia. Hematology, 2019(1), 548-556. https://doi.org/10.1182/hematology.2019000059 Schlenk, R. F., Weber, D., Fiedler, W., Salih, H. R., Wulf, G., Salwender, H., Schroeder, T., Kindler, T., Lübbert, M., Wolf, D., Westermann, J., Kraemer, D., Götze, K. S., Horst, H.-A., Krauter, J., Girschikofsky, M., Ringhoffer, M., Südhoff, T., Held, G., . . . Group, o. b. o. t. G.-A. A. S. (2019). Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood, 133(8), 840-851. https://doi.org/10.1182/blood-2018-08-869453 Short, N. J., Rytting, M. E., & Cortes, J. E. (2018). Acute myeloid leukaemia. The Lancet, 392(10147), 593-606. https://doi.org/10.1016/S0140-6736(18)31041-9 Stein, E., Xie, J., Duchesneau, E., Bhattacharyya, S., Vudumula, U., Ndife, B., Bonifacio, G., Guerin, A., Li, N., & Joseph, G. (2019). Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States. PharmacoEconomics, 37(2), 239-253. https://doi.org/10.1007/s40273-018-0732-4 Stein E, e. a. (2018). Midostaurin cost effective for FLT3-mutated AML. PharmacoEconomics & Outcomes News, 816(1), 21-21. https://doi.org/10.1007/s40274-018-5441-x Stein, E. M., Shukla, N., & Altman, J. K. (2019). Acute myeloid leukemia. In A. Cuker, J. K. Altman, A. T. Gerds, & T. Wun (Eds.), American Society of Hematology Self-Assessment Program, Seventh Edition (pp. 0). American Society of Hematology. https://doi.org/10.1182/ashsap7.chapter20 Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., Lo-Coco, F., Klisovic, R. B., Wei, A., Sierra, J., Sanz, M. A., Brandwein, J. M., de Witte, T., Niederwieser, D., Appelbaum, F. R., . . . Döhner, H. (2017). Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. New England Journal of Medicine, 377(5), 454-464. https://doi.org/10.1056/NEJMoa1614359 Thol, F. (2021). What to use to treat AML: the role of emerging therapies. Hematology, 2021(1), 16-23. https://doi.org/10.1182/hematology.2021000309 Tremblay, G., Cariou, C., Recher, C., Dolph, M., Brandt, P., Blanc, A.-S., & Forsythe, A. (2020). Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France. The European Journal of Health Economics, 21(4), 543-555. Tremblay, G., Dolph, M., Patel, S., Brandt, P., & Forsythe, A. (2018). Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom. Cost Effectiveness and Resource Allocation, 16(1), 33. https://doi.org/10.1186/s12962-018-0153-4 Vaughn, J. E., Shankaran, V., & Walter, R. B. (2019). Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come? Curr Hematol Malig Rep, 14(3), 171-178. https://doi.org/10.1007/s11899-019-00510-2 Venugopal, S., Takahashi, K., Daver, N., Maiti, A., Borthakur, G., Loghavi, S., Short, N. J., Ohanian, M., Masarova, L., Issa, G., Wang, X., Carlos, B.-R., Yilmaz, M., Kadia, T., Andreeff, M., Ravandi, F., Konopleva, M., Kantarjian, H. M., & DiNardo, C. D. (2022). Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer Journal, 12(1), 10. https://doi.org/10.1038/s41408-021-00604-2 Viechtbauer, W. (2010). Conducting meta-analyses in R with the metafor package. Journal of Statistical Software, 36(3), 1-48. https://doi.org/https://doi.org/10.18637/jss.v036.i03 Wei, A. H., Montesinos, P., Ivanov, V., DiNardo, C. D., Novak, J., Laribi, K., Kim, I., Stevens, D. A., Fiedler, W., Pagoni, M., Samoilova, O., Hu, Y., Anagnostopoulos, A., Bergeron, J., Hou, J.-Z., Murthy, V., Yamauchi, T., McDonald, A., Chyla, B., . . . Panayiotidis, P. (2020). Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood, 135(24), 2137-2145. https://doi.org/10.1182/blood.2020004856 Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., Agarwal, A., Blucher, A., Borate, U., Bryant, J., Burke, R., Carlos, A., Carpenter, R., Carroll, J., Chang, B. H., . . . Druker, B. J. (2018). Functional genomic landscape of acute myeloid leukaemia. Nature, 562(7728), 526-531. https://doi.org/10.1038/s41586-018-0623-z Bottomly, D., Long, N., Schultz, A. R., Kurtz, S. E., Tognon, C. E., Johnson, K., Abel, M., Agarwal, A., Avaylon, S., Benton, E., Blucher, A., Borate, U., Braun, T. P., Brown, J., Bryant, J., Burke, R., Carlos, A., Chang, B. H., Cho, H. J., . . . Tyner, J. W. (2022). Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell, 40(8), 850-864.e859. https://doi.org/10.1016/j.ccell.2022.07.002 Beat AML 1.0 http://www.vizome.org/ Hou, H.-A., Chou, W.-C., & Tien, H.-F. (2011). Genetic Alterations and Their Clinical Implications in Acute Myeloid Leukemia. Koschmieder S. Myeloid Leukemia-Basic Mechanisms of Leukemogenesis, 163-184. Tsai, C. H., Hou, H. A., Tang, J. L., Liu, C. Y., Lin, C. C., Chou, W. C., Tseng, M. H., Chiang, Y. C., Kuo, Y. Y., Liu, M. C., Liu, C. W., Lin, L. I., Tsay, W., Yao, M., Li, C. C., Huang, S. Y., Ko, B. S., Hsu, S. C., Chen, C. Y., . . . Tien, H. F. (2016). Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia, 30(7), 1485-1492. https://doi.org/10.1038/leu.2016.65 伍焜玉. (2010/11/26). 血液的奧祕：你必須知道的血液知識. 天下文化. Chia-Hsun, L. (2022). Cost Effectiveness Analysis for Targeted Therapy in Patients with Acute Myeloid Leukemia National Taiwan University].
dc.identifier.uri	http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84675	-
dc.description.abstract	急性骨髓性白血病(Acute myeloid leukemia, AML)在各種成人血癌裡是發生率最高的白血病，以癌症整體存活狀況來看，急性骨髓性白血病患者存活率低，其標準治療策略是7+3方案，七天阿糖胞苷(Cytarabine)加上三天蒽環類藥物(Anthracycline)。然而「7+3」方案的密集誘導化療有時會造成患者身體負荷過重，特別在年長或嚴重共病的患者。到目前已有多種臨床試驗採用新型的藥物來進行治療，自2017年至今已有十種藥物獲得美國Food and Drug Administration (FDA)，包括Venetoclax及針對FLT3抑制劑, IDH1/2抑制劑等標靶藥物或其他新穎治療藥物運用於臨床試驗中。大部分的標靶治療價格昂貴且未獲台灣FDA核准或不在台灣全民健康保險範圍內，因此本研究提供治療急性骨髓性白血病患者在透過各項分子檢測及標靶治療上的成本效益分析。基於決策分析建立模型，所建構之馬可夫模型 (Markov Model) 提供量性決策分析，並考慮決策過程中的多項不確定因素，評估相較於「7+3」方案治療，使用標靶治療或者利用危險分層對高風險族群之標靶治療結合中低風險族群之「7+3」方案之精準方案的成本效益分析。效益部分利用新治療和「7+3」方案治療患者所得的生活品質調整後生命年(Quality-adjusted life year, QALY)進行估計；成本部分包括基因檢測、治療及住院等等。本研究利用臺灣本土參數所建構的成本效益分析得到標靶治療與精準治療策略相較於「7+3」方案治療的增量成本效益比(Incremental cost-effectiveness ratio, ICER) ，亦即當每多增加一單位的生活品質調整生命年時將會分別需要9,696美元及11,334美元，低於2021年3倍的國民人均生產毛額98,361美元，機率性成本效益分析顯示當願付成本超過7500美元時精準策略為最具成本效益的抉擇，當願付成本超過7500美元時，標靶治療為最可能具成本效益之策略。以美國情境進行分析時，65歲男性標靶治療比上「7+3」方案治療的ICER為 65,628美元，金額小於付費意願(Willingness to pay, WTP)閥值98,361 美元，因此標靶治療對急性骨髓性白血病患者來說是一種具有成本效益的選擇。	zh_TW
dc.description.abstract	Acute myeloid leukemia (AML) is the most common acute adult leukemia and poor survival in the patients new diagnosed with AML. The standard treatment for treating AML is ‘7+3’ regimen, over 4 decades already, which is 7 days of Cytarabine and 3 days of an Anthracycline. However, the intensive induction chemotherapy like ‘7+3’ is sometimes unbearable, especially in elderly patients. Many clinical trials have designed to use novel agents for an alternative treatment. Ten agents received approved by U.S. Food and Drug Administration (FDA) for various indications, including several targeted therapies such as Venetoclax, FLT3 inhibitors and IDH inhibitors, they are available in clinical trials for treating AML patients since 2017. However, in most of targeted therapies are expensive and still not in the coverage of National Health Insurance in Taiwan. This study aimed to provide a cost effectiveness analysis for genetic screening and targeted therapies for treating AML patients. Based on the decision-analytical modelling, our goal is to evaluate the cost effectiveness of using new treatment like targeted therapies with ‘7+3’ standard treatment through the modelling of Markov models for providing quantitative analysis and considering the uncertain factors during the decision making process. We used the empirical results from Taiwanese data for the parameters of Markov decision analysis. Compared with ‘7+3’ standard treatment, the incremental cost-effectiveness ratio (ICER) for personalized strategy and target therapy was $9,696 and $11,334, respectively, for one additional quality-adjusted life year (QALY) gained. Both ICERs were lower than three times of GDP per capita, 98,361. Analysis with the probabilistic approach shows the same results.	en
dc.description.provenance	Made available in DSpace on 2023-03-19T22:20:06Z (GMT). No. of bitstreams: 1 U0001-2609202221325700.pdf: 2412045 bytes, checksum: eb37316dc6ef5510e1bf215413d92f13 (MD5) Previous issue date: 2022	en
dc.description.tableofcontents	口試委員會審定書 i 誌謝Acknowledgements ii 中文摘要 iii ABSTRACT iv 目錄 v 圖目錄 vii 表目錄 viii 第一章緒論 1 第二章文獻探討 3 2.1自然病史及醫療選擇策略 3 2.2 精準治療 8 2.3 標靶治療/新興療法 10 2.4 存活分析及風險函數 12 2.5醫療之成本效益分析(Cost-effectiveness analysis, CEA) 14 第三章研究方法及材料 23 3.1 資料來源 23 3.2 研究方法與建模 24 第四章研究結果 35 4.1 模型一 : 三種治療策略之效益分析 35 4.2 模型一：機率性敏感度分析(Probability Sensitivity Analysis, PSA) 36 4.3 模型二 : 傳統治療、標靶/新興療法策略之效益分析 36 4.4 模型二：決策系统敏感度分析(Deterministic Sensitivity Analysis，DSA)與機率性敏感度分析(Probability Sensitivity Analysis, PSA) 37 第五章討論與結論 45 REFERENCE 48
dc.language.iso	zh-TW
dc.subject	急性骨髓性白血病	zh_TW
dc.subject	效益分析	zh_TW
dc.subject	Cost-effectiveness analysis	en
dc.subject	AML	en
dc.subject	CEA	en
dc.title	標靶治療於急性骨髓性白血病成本效益分析	zh_TW
dc.title	Cost Effectiveness Analysis for Targeted Therapy in Patients with Acute Myeloid Leukemia	en
dc.type	Thesis
dc.date.schoolyear	110-2
dc.description.degree	碩士
dc.contributor.oralexamcommittee	陳祈玲(Chi-Ling Chen)
dc.subject.keyword	效益分析,急性骨髓性白血病,	zh_TW
dc.subject.keyword	Cost-effectiveness analysis,CEA,AML,	en
dc.relation.page	52
dc.identifier.doi	10.6342/NTU202204123
dc.rights.note	同意授權(限校園內公開)
dc.date.accepted	2022-09-29
dc.contributor.author-college	公共衛生學院	zh_TW
dc.contributor.author-dept	流行病學與預防醫學研究所	zh_TW
dc.date.embargo-lift	2022-10-17	-
顯示於系所單位：	流行病學與預防醫學研究所

文件中的檔案：

檔案	大小	格式
U0001-2609202221325700.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務）	2.36 MB	Adobe PDF

顯示文件簡單紀錄

系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。